Scaling Advanced Therapies and U.S. Biomanufacturing

ElevateBio is industrializing cell and gene therapy manufacturing to bring life-changing genetic medicines to improve the lives of patients and their families.

Henry Ford didn't invent the automobile, but in 1913, he transformed how it was made. The moving assembly line drastically reduced the cost of a car and turned a luxury into something accessible to millions. Today, a parallel transformation is underway in medicine. Cell and gene therapies represent a fundamentally new class of treatment. Rather than managing symptoms with traditional drugs, these advanced therapies harness a patient's own cells or genes to correct disease at its source, offering the potential for life-transformative therapies or even single-treatment cures. 

Since the first FDA-approved cell therapy in 2017, the field has moved from scientific breakthrough to medical reality. But manufacturing and delivering these therapies at scale remains the greatest challenge, and one that ElevateBio, a U.S.-based biomanufacturing company, is working to solve.

The science of genetic medicine has reached an inflection point. Decades of research have yielded multiple approved cell therapies. Yet accessibility remains constrained, not by what's biologically possible, but by how these medicines are manufactured. Cell therapy manufacturing is inherently personal: very often, one patient's cells must be collected, engineered, and returned to that same patient. Doing this reliably at a wide-spread scale requires infrastructure, expertise, and precision few can deliver.

ElevateBio was established in 2017 to help biopharma companies industrialize these breakthroughs. Its manufacturing facility in Waltham, Massachusetts operates as a one-stop platform from clinical through commercial manufacturing, capable of supporting thousands of batches annually. Now, ElevateBio is expanding with a new facility in Pittsburgh: a factory of the future leveraging robotics, AI, and digital tools to reduce costs and increase manufacturing scale.

In most of the industry, drug discovery and manufacturing operate in silos. Therapies are designed in the lab and only later adapted for manufacturing. ElevateBio eliminates that gap. In addition to manufacturing therapies for biopharma partners, the company has built its own gene editing platform – technology that makes edits directly to the genome with the potential to treat or even cure disease. These tools help partners develop their own therapeutic programs and maximize their chance of reaching patients.

On the manufacturing side, automation, advanced analytics, and process innovation drive down costs while increasing throughput across every batch. This integration matters as these advanced therapies expand into autoimmune diseases, which can have even larger patient populations than oncology indications. The industry needs reliable, U.S.-based manufacturing infrastructure dedicated to advanced therapies that can keep pace – and ElevateBio is building it.

From Waltham to Pittsburgh, ElevateBio is growing its American manufacturing footprint to make production more accessible and globally scalable. Its gene editing services complement the manufacturing platform, giving partners a seamless path from concept through commercialization. The next breakthroughs in genetic medicine won't come from science alone. They'll come from the ability to manufacture these therapies reliably, at scale, here in the United States. ElevateBio is building that future, powering the creation of advanced therapies, at a speed the world deserves.